One Biosciences, a clinical-grade single-cell tumor profiling biotech spun out of Institut Curie, secured €3.3 million in joint financing with Institut Curie through the France 2030 i-Démo 5 program, as announced from Paris. The funding will accelerate development of what the partners describe as the first single-cell diagnostic test targeting triple-negative breast cancer. The announcement did not characterize the financing as a venture equity round and did not disclose investors, valuation, or business metrics such as revenue, clients, or employee count.